Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Show Only Open Trials
1.
Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
- Study Status: Open to Enrollment
- Sponsor: Calistoga
- Disease Status and/or Stage: Refractory Indolent B-cell non-Hodgkin Lymphoma
2.
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Untreated or Relapsed Chronic Lymphocytic Leukemia
3.
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Chronic Lymphocytic Leukemia
4.
A long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: Pharmacyclics, Inc.
5.
CALGB 10404: A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
- Study Status: Open to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Chronic Lymphocytic Leukemia (CLL)
6.
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies
- Study Status: Closed to Enrollment
- Sponsor: Calistoga Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
